{"id":399576,"date":"2020-12-15T06:03:09","date_gmt":"2020-12-15T11:03:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=399576"},"modified":"2020-12-15T06:03:09","modified_gmt":"2020-12-15T11:03:09","slug":"immuron-sars-cov-2-research-agreement-with-monash-university","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/","title":{"rendered":"Immuron SARS-CoV-2 Research Agreement with Monash University"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <strong>Key Points<\/strong><br \/>\n        \n      <\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">\n          <strong>Immuron\u2019s Hyper-immune Bovine Colostrum, used to manufacture Travelan<sup>\u00ae<\/sup> and Protectyn<sup>\u00ae<\/sup>, <\/strong><br \/>\n          <strong>demonstrated antiviral activity against the SARS-CoV-2\/COVID-19 virus in laboratory studies.<\/strong><\/p>\n<\/li>\n<li style=\"text-align:justify\">\n          <strong>A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance\/s in Immuron\u2019s marketed products (IMM-124E).<\/strong><br \/>\n          \n        <\/li>\n<\/ul>\n<p align=\"justify\">MELBOURNE, Australia, Dec.  15, 2020  (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and international research collaborators to advance this work and assist in the further characterization of the neutralization activity of SARS-CoV-2 observed with Immuron\u2019s commercial hyper-immune colostrum used to manufacture the company\u2019s flag ship commercially available and over-the-counter gastrointestinal and digestive health immune supplements Travelan<sup>\u00ae<\/sup> and Protectyn<sup>\u00ae<\/sup>.<\/p>\n<p align=\"justify\">The company has recently executed a new Research Agreement with Monash University to develop new assays to evaluate the efficacy of IMM-124E, the active pharmaceutical ingredient used to manufacture Travelan<sup>\u00ae<\/sup> and Protectyn<sup>\u00ae<\/sup> to further our understanding of the inhibitory substance\/s in our commercial products.<\/p>\n<p align=\"justify\">The research team will be led by Dr Melanie Hutton and Professor Dena Lyras, Deputy Director, Biomedicine Discovery Institute and Deputy Head, Department of Microbiology who will utilize two new recombinant reagents, the SARS-CoV-2 Spike protein, a receptor binding domain protein as well as an antibody positive human serum sample obtained from Melbourne\u2019s Peter Doherty Institute for Infection and Immunity.<\/p>\n<p align=\"justify\">\u201cWe have been very fortunate to obtain access to the SARS-CoV-2 recombinant proteins developed at the Peter Doherty Institute for Infection and Immunity,\u201d said Professor Lyras. \u201cThese reagents will be used to initiate the research work and to develop a suitable assay for evaluating the inhibitory efficacy of IMM-124E. Furthermore, specific immune components will be purified from IMM-124E and will be used to evaluate their ability to inhibit the binding of an antibody positive human serum sample to specific COVID-19 proteins, such as the spike protein which is crucial for cell entry,\u201d said Dr Hutton.<\/p>\n<p align=\"justify\">This release has been authorised by the directors of Immuron Limited.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>COM<\/strong><br \/>\n            <strong>P<\/strong><br \/>\n            <strong>ANY CON<\/strong><br \/>\n            <strong>T<\/strong><br \/>\n            <strong>ACT:<\/strong><br \/>\n            <br \/>\n            <strong>Dr Jerry Kanellos, Ph.D.<\/strong><br \/>\n            <br \/>Chief Executive Officer<br \/>Ph: +61 (0)3 9824 5254<br \/>info@immuron.com<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For more information visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=facL-gLlFPuXFRGnAoZmstvWEf_3jqwfAMr4JwVpWNE6DivzxxqnwH70OyLenGxHQkXpm3_iik75zaVnwz2YYfBftgIUmYNxlKWhMdEgXfI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/www.immuron.com<\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/b5720de8-fdb2-4d74-9fbc-3575425c5482\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Key Points Immuron\u2019s Hyper-immune Bovine Colostrum, used to manufacture Travelan\u00ae and Protectyn\u00ae, demonstrated antiviral activity against the SARS-CoV-2\/COVID-19 virus in laboratory studies. A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance\/s in Immuron\u2019s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuron SARS-CoV-2 Research Agreement with Monash University&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-399576","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Key Points Immuron\u2019s Hyper-immune Bovine Colostrum, used to manufacture Travelan\u00ae and Protectyn\u00ae, demonstrated antiviral activity against the SARS-CoV-2\/COVID-19 virus in laboratory studies. A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance\/s in Immuron\u2019s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and &hellip; Continue reading &quot;Immuron SARS-CoV-2 Research Agreement with Monash University&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-15T11:03:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuron SARS-CoV-2 Research Agreement with Monash University\",\"datePublished\":\"2020-12-15T11:03:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/\"},\"wordCount\":418,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/\",\"name\":\"Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\",\"datePublished\":\"2020-12-15T11:03:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-sars-cov-2-research-agreement-with-monash-university\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuron SARS-CoV-2 Research Agreement with Monash University\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/","og_locale":"en_US","og_type":"article","og_title":"Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk","og_description":"Key Points Immuron\u2019s Hyper-immune Bovine Colostrum, used to manufacture Travelan\u00ae and Protectyn\u00ae, demonstrated antiviral activity against the SARS-CoV-2\/COVID-19 virus in laboratory studies. A New Research Services Agreement has been executed with Monash University to advance the SARS-CoV-2 findings and to further research and identify the inhibitory substance\/s in Immuron\u2019s marketed products (IMM-124E). MELBOURNE, Australia, Dec. 15, 2020 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the prevention and treatment of gut pathogens, today is pleased to provide shareholders and the market with an update on progress made for the further development of the anti-viral activity of IMM-124E. The company has been actively engaging with local, national, and &hellip; Continue reading \"Immuron SARS-CoV-2 Research Agreement with Monash University\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-15T11:03:09+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuron SARS-CoV-2 Research Agreement with Monash University","datePublished":"2020-12-15T11:03:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/"},"wordCount":418,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/","name":"Immuron SARS-CoV-2 Research Agreement with Monash University - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=","datePublished":"2020-12-15T11:03:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMjE3NCMzODgxNDQ1IzIwMjAyOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-sars-cov-2-research-agreement-with-monash-university\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuron SARS-CoV-2 Research Agreement with Monash University"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399576","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=399576"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/399576\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=399576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=399576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=399576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}